drugset / Trial / NCT04095689
Docetaxel Chemotherapy and Pembrolizumab Plus Interleukin-12 Gene Therapy in Triple Negative Breast Cancer
Phase 2
Terminated
8 enrolled
The Methodist Hospital Research Institute
Merck Sharp & Dohme LLC · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to test the safety and effectiveness of docetaxel chemotherapy and pembrolizumab plus adenoviral-mediated interleukin-12 (ADV/IL-12) gene therapy in patients with anthracycline-refractory, triple negative breast cancer (TNBC).
Timeline
- Start
- 2021-05-12
- Primary completion
- 2024-06-03
- Completion
- 2024-06-03
Outcome
Outcome not reported
Stopped: “Stopping rules met per protocol, trial will be terminated”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | IL-12 gene therapy | Unknown | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |